WO2015137724A1 - 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 - Google Patents
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 Download PDFInfo
- Publication number
- WO2015137724A1 WO2015137724A1 PCT/KR2015/002356 KR2015002356W WO2015137724A1 WO 2015137724 A1 WO2015137724 A1 WO 2015137724A1 KR 2015002356 W KR2015002356 W KR 2015002356W WO 2015137724 A1 WO2015137724 A1 WO 2015137724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cancer
- specific
- culture
- autologous
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 118
- 239000000427 antigen Substances 0.000 title claims abstract description 86
- 108091007433 antigens Proteins 0.000 title claims abstract description 85
- 102000036639 antigens Human genes 0.000 title claims abstract description 85
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000002062 proliferating effect Effects 0.000 title abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 71
- 210000004027 cell Anatomy 0.000 claims abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
- 210000004369 blood Anatomy 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 21
- 108010002350 Interleukin-2 Proteins 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 16
- 210000004748 cultured cell Anatomy 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 238000012216 screening Methods 0.000 description 49
- 239000002609 medium Substances 0.000 description 26
- 102100022748 Wilms tumor protein Human genes 0.000 description 22
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 17
- 201000005202 lung cancer Diseases 0.000 description 17
- 208000020816 lung neoplasm Diseases 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 206010039491 Sarcoma Diseases 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 description 8
- 206010017758 gastric cancer Diseases 0.000 description 8
- 201000011549 stomach cancer Diseases 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 5
- 108010075704 HLA-A Antigens Proteins 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000011932 ovarian sarcoma Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101000889335 Bombyx mori Trypsin inhibitor Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 239000006296 mab medium Substances 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Definitions
- the present invention relates to a method for the isolation and proliferation of autologous cancer antigen specific CD8 + T cells, and more particularly, to select and select epitopes recognized by CD8 + T cells from autologous antigens present in the blood of individual cancer patients.
- the present invention relates to a method for isolating CD8 + T cells specific for autocancer antigens using peptides of epitopes, and a method for mass proliferation of CD8 + T cells using the same.
- CD8 + T cells have relatively simple functions compared to other cells such as dendritic cells, CD4 + T, and NK cells, there are fewer chances of unexpected side effects in anticancer immunotherapy.
- MHC class I / peptide multimers are used to isolate antigen-specific CD8 + T cells.However, in this method, apoptosis is high due to apoptosis after cell separation, thereby producing a sufficient amount of antigen-specific CD8 + T cells. There was a disadvantage of having to culture for a long time. Therefore, a surrogate marker capable of separating antigen-specific CD8 + T cells by replacing MHC multimers that stimulate T cell receptors (TCR) is needed. (CD137) has been studied.
- 4-1BB is expressed in activated T cells as inducible co-stimulatory molecules, and in particular enhances the activity of CD8 + T cells, as well as anti-apoptotic molecules such as Bcl-2, Bcl-XL, Bfl-1, etc. It is well known to increase the expression of anti-apoptotic molecules, thereby inhibiting activation-induced cell death (AICD).
- the characteristics of the 4-1BB stimulus are suitable for cancer treatment, and based on this, the effect of cancer treatment with anti-4-1BB mAb was verified using an animal model.
- an object of the present invention is to isolate and proliferate autologous antigen-specific CD8 + T cells capable of selectively isolating and mass culturing CD8 + T cells specific for autologous antigens present in an extremely low rate in the body within 31 days. To provide.
- the present invention comprises the steps of: a) screening auto-antigen CD8 + T cell epitopes present in the blood of cancer patients; b) culturing the peripheral blood mononuclear cells (PBMCs) isolated from the blood of cancer patients in medium with peptides of said epitope and IL-2; c) inducing 4-1BB expression by adding the same peptide to the cultured cells as in step b); And d) culturing the 4-1BB expression-induced cells in a culture plate coated with an anti-4-1BB antibody, and then removing the non-attached cells of the autologous antigen-specific CD8 + T cells.
- PBMCs peripheral blood mononuclear cells
- the self-cancer antigen of step a) may be selected from the group consisting of hTERT, WT1, NY-ESO1 and MAGE-A3.
- the epitope in step b) may be a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 15.
- step c) the expression induction of step c) is characterized in that the culture for 12 to 36 hours.
- the culturing of step d) may be performed for 1 to 20 minutes.
- the present invention is cultured after suspending the isolated autoantigen specific CD8 + T cells and irradiated allogeneic PBMC with a medium containing IL-2, anti-CD3 antibody and autologous plasma. It provides a method for mass culturing auto-cancer antigen-specific CD8 + T cells, including injecting into a bag, and incubating the medium further.
- the PBMC may be isolated from the normal donor.
- the culture may be performed for 4 to 15 days.
- CD8 + T cells specific for autologous cancer antigens can be isolated using peptides of autologous cancer antigen CD8 T cell epitopes present in the blood of individual cancer patients other than foreign antigens. Therefore, the use of T cells recognizing autologous antigens present in an extremely low rate in a normal person separated by the method of the present invention can effectively select and remove cancer cells derived from the cells of cancer patients themselves.
- FIG. 1 is a view illustrating a selective isolation and mass culture process of autologous cancer antigen specific CD8 + T cells according to the present invention.
- FIG. 2 is a process flow diagram of an epitope screening process according to the present invention.
- FIG. 3 is a diagram showing the results of hTERT epitope screening using PBMC obtained from a healthy doner.
- FIG. 4 is a diagram showing the results of WT1 epitope screening using PBMC obtained from a normal person.
- 5 to 7 show hTERT epitope screening results using PBMCs obtained from gastric cancer, lung cancer and pancreatic cancer patients, respectively.
- 15 is a diagram illustrating a pilot production process of a WT1 T cell therapeutic agent.
- FIG. 16 is a diagram illustrating a pilot production process of NY-ES01 T cell therapeutic agent.
- 17 is a diagram illustrating a pilot production process of a MAGE-A3 T cell therapeutic agent.
- cancer cells are derived from the cells constituting our body, selective removal and mass culturing of self tumor Ag-specific CD8 + T cells overexpressed in cancer cells are required to selectively remove cancer cells.
- T cells that recognize autologous cancer antigens are not only present in very low proportions in normal individuals, but also in a state in which activity is inhibited by immune tolerance. Therefore, a standardized process for selectively separating and culturing auto-cancer antigen specific CD8 + T cells from cancer patients has not been developed yet.
- the present inventors have selectively separated autologous antigen specific CD8 + T cells, such as hTERT, WT1, NY-ESO1, and MAGE-A3, which are present in the body at an extremely low rate by using an anti- 4-1BB antibody.
- CD8 + T cells such as hTERT, WT1, NY-ESO1, and MAGE-A3
- the present invention provides a method for separating autologous antigen specific CD8 + T cells.
- the method for separating autologous cancer-specific CD8 + T cells of the present invention comprises the steps of: a) selecting autologous antigenic CD8 + T cell epitopes present in the blood of cancer patients; b) culturing the peripheral blood mononuclear cells (PBMCs) isolated from the blood of cancer patients in medium with peptides of said epitope and IL-2; c) inducing 4-1BB expression by adding the same peptide to the cultured cells as in step b); And d) culturing the cells induced with 4-1BB expression in a culture plate coated with an anti-4-1BB antibody and then removing the unattached cells.
- PBMCs peripheral blood mononuclear cells
- the self-cancer antigen of step a) may be any cancer antigen present in the cancer patient's own body, and an appropriate auto-cancer antigen may be selected and used according to the carcinoma.
- an appropriate auto-cancer antigen may be selected and used according to the carcinoma.
- hTERT GenBank: BAC11010.1
- WT1 GenBank: AAO61088.1
- NY-ESO1 GenBank: CAA05908.1
- MAGE-A3 NCBI Reference Sequence: NP_005353.1
- the hTERT is an enzyme that synthesizes telomeric DNA at the end of a chromosome, and cancer cells function excessively by activating this enzyme to avoid telomere-dependent cell death and target various solid cancers including lung cancer, gastric cancer and pancreatic cancer. It is known as an antigen (Kim NW, et al. Science . 1994; 266: 2011-2015), and WT1 is a gene associated with Wilms tumor, which encodes a zinc finger transcription factor to prevent cell proliferation, differentiation, apoptosis, and organ development. As a protein involved, it is known as a target antigen of cerebrospinal cancer, lung cancer, etc. (Call KM, et al., Cell . 1990.
- the NY-ESO1 is one of the proteins belonging to cancer testis antigen (CTA), and is well known to express various cancer cells including germ cells, sarcoma, and breast cancer, but what functions do they have in these cells? Not well known (Gnjatic S, et al., Adv Cancer Res . 2006; 95: 1-30).
- CTA cancer testis antigen
- MAGE-A3 is a protein belonging to the melanoma-associated antigen family, it is not known what function it performs in normal cells. However, MAGE-A3 is known to overexpress various cancer cells including lung cancer, sarcoma, and melanoma. It has been evaluated as a target antigen (Decoster L, et al., Ann Oncol . 2012 Jun; 23 (6): 1387-93).
- the epitope in step b) is characterized in that the peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 15.
- the medium of step b) is characterized in that the medium containing autologous plasma, and the culture of step b) is characterized in that it is carried out for 12 to 16 days.
- step c) the expression induction of step c) is characterized in that the culture for 12 to 36 hours, the culture of step d) is characterized in that it is carried out for 1 to 20 minutes.
- the present invention was suspended in a medium containing IL-2, anti-CD3 antibody and autologous plasma of autologous antigen-specific CD8 + T cells and irradiated allogeneic PBMCs isolated by the above-described separation method It is then injected into the culture bag, and provides a method for mass culture of autologous antigen-specific CD8 + T cells comprising the additional culture of the medium.
- the PBMC is characterized in that it is separated from the normal donor, the culture is characterized in that it is performed for 4 to 15 days.
- the medium may be additionally injected on the 4th, 7th, 9th, 11th and 14th days of culture while the culture is performed.
- the present invention selectively propagates and isolates autologous cancer antigen specific CD8 T cells using peptides.
- Epitopes of autologous cancer antigens recognized by CD8 T cells are different depending on HLA-A type and condition of each patient. Therefore, epitope screening is used to detect autologous antigen CD8 T cell epitope present in the blood of individual cancer patients. Three to four kinds of peptides for the production of T cell therapeutics were selected.
- autologous antigen-specific CD8 T cells are present in 0.1% or less in blood, they are specific for peptides derived from autologous antigens by incubating for 14 days with 3-4 kinds of peptides for production and IL-2 in PBMCs isolated from blood. Induces proliferation of CD8 T cells. All cells are harvested on day 14 of culture and reactivated with the same peptides for 24 hours to induce peptide-specific CD8 T cells to simultaneously express 4-1BB.
- the cells reactivated with peptides are cultured on an anti-4-1BB antibody-coated culture plate and incubated for 10 minutes to attach 4-1BB-expressing CD8 T cells, and all unsolicited cells are washed out. Thereafter, the medium containing IL-2 is added to incubate for two days so that the isolated T cells fall into the culture plate with proliferation.
- CD8 T cells 5 ⁇ 10 5 cells isolated in a 1L culture bag, irradiated allogeneic PBMCs 1 ⁇ 10 8 cells, 1000U / ml IL-2, 40ng anti-CD3 mAb Medium is added daily to mass cultivate the cells at a level of ⁇ 10 9 cells / L and propagate to levels that can be administered to cancer patients.
- PBMCs peripheral blood mononuclear cells
- CTL medium RPMI1640 medium + 4 mM
- Incubation in a CO 2 incubator was performed by analyzing algorithms and adding peptides of each epitope selected to each tube at a concentration of 1 ⁇ g / ml.
- 1 ml of CTL medium containing 50 U / ml IL-2 was added to each tube.
- CTL medium containing 50 U / ml IL-2 was added.
- the cells were washed three times by adding RPMI1640 medium to each tube and centrifuging at 1400 rpm for 5 minutes.
- FIG. 2 is a process flow diagram of an epitope screening process according to the present invention.
- Anti-CD8-PE-Cy5, anti-4-1BB-PE used in the experiment was purchased from eBioscience (San Diego, Calif.).
- RPMI1640, L-glutamine, HEPES, 2-mercaptoethanol were purchased from Invitrogen, San Diego, Calif.
- hTERT (GenBank: BAC11010.1), WT1 (GenBank: AAO61088.1), NY-ESO1 (GenBank: CAA05908.1), MAGE-A3 (NCBI Reference Sequence: NP_005353.1) are used for anticancer immunotherapy in various ways. Representative auto-cancer antigens are being selected for carcinomas applicable to these four cancer antigens are summarized in Table 1 below.
- CD8 T cell epitopes The amino acid sequences of selected autologous antigens were analyzed by algorithms to determine the amino acid sequences presumed to be CD8 T cell epitopes (CTLPred: http://www.imtech.res.in/raghava/ctlpred/, NetCTL: http: //www.cbs.dtu.dk/services/NetCTL/, SYFPEITHI: http://www.syfpeithi.de/) to chemically synthesize peptides on selected epitopes (Peptron Inc; www.peptron.com) Used for epitope screening.
- CD8 T cell epitopes selected from each autologous antigen are shown in Tables 2 to 5 below.
- FIG. Epitope screening as described above was performed.
- hTERT epitope screening was mainly for gastric, lung and pancreatic cancer
- WT1 epitope screening was for cerebrospinal and lung cancer
- NY-ESO1 epitope screening for ovarian and sarcoma
- MAGE-A3 epitope screening for sarcoma and lung cancer was performed.
- FIG. 3 is a diagram showing the results of hTERT epitope screening using PBMC obtained from a healthy doner.
- FIG. 4 is a diagram showing the results of WT1 epitope screening using PBMC obtained from a normal person.
- CD8 T cell epitopes of hTERT and WT1 failed to induce T cell responses from PBMCs isolated from normal human blood. Therefore, it was confirmed that the selected epitopes of the present invention were not recognized by T cells of normal persons.
- 5 to 7 show hTERT epitope screening results using PBMCs obtained from gastric cancer, lung cancer and pancreatic cancer patients, respectively.
- Table 7 shows the results of analyzing hTERT epitope screening using PBMC obtained from gastric cancer patients.
- Table 8 below shows the results of hTERT epitope screening using PBMC obtained from lung cancer patients.
- Table 9 shows the results of analyzing hTERT epitope screening using PBMC obtained from pancreatic cancer patients.
- Table 10 shows the results of analyzing WT1 epitope screening using PBMC obtained from patients with brain tumors.
- Table 11 shows the results of analyzing WT1 epitope screening using PBMC obtained from lung cancer patients.
- Table 12 shows the analysis of NY-ESO1 epitope screening using PBMC obtained from ovarian cancer patients.
- Table 13 shows the results of analyzing WT1 epitope screening using PBMC obtained from sarcoma patients.
- Table 14 below shows the results of MAGE-A3 epitope screening using PBMC obtained from sarcoma patients.
- Table 15 below shows the results of MAGE-A3 epitope screening using PBMC obtained from lung cancer patients.
- Selected peptides include hTERT peptides: CLKELVARV (SEQ ID NO: 1), PLFLELL (SEQ ID NO: 2), AAVTPAA (SEQ ID NO: 3); WT1 peptides: SLGEQQVSV (SEQ ID NO: 4), RMFPNAPVL (SEQ ID NO: 5), CMTWNQMNL (SEQ ID NO: 6), VLDFAPPGA (SEQ ID NO: 7); NY-ESO1 peptide: SISSCLQQL (SEQ ID NO: 8), RLLEFYLAM (SEQ ID NO: 9), GVLLKEFTV (SEQ ID NO: 10), ILTIRLTAA (SEQ ID NO: 11); And MAGE-A3 peptide: LLIIVLAII (SEQ ID NO: 12), KIWEELSVL (SEQ ID NO: 13), LVFGIELMEV (SEQ ID NO: 14), SLPTTMNYPL (SEQ ID NO: 15).
- Epitope screening selects 3-4 epitope peptides for each autologous antigen suitable for T cell therapeutic preparation, and then uses these peptides for hTERT, WT1, NY-ESO1, and MAGE-A3 specific T cells. Trial production of therapeutics was performed. Production of T cell therapy consists of three stages of primary proliferation, isolation, and mass culture of autologous anticancer T cells.
- 50 ml blood was isolated from cancer patients whose epitope screening confirmed the presence of at least one epitope with score 3 or greater.
- PBMC Separation from Patient's Blood 7 ml of blood was slowly flowed into a 15 ml cornical tube filled with 7 ml Ficoll-hypaque and overlayed on top of the Ficoll solution. The tube was centrifuged at 2000 rpm for 20 minutes, and only white cell layers located between Ficoll and plasma were collected and washed and used as PBMC.
- the isolated PBMC is suspended in CTL medium (RPMI1640 medium + 4 mM L-glutamine + 12.5 mM HEPES + 50 ⁇ M 2-mercaptoethanol + 3% autoplasma) at 1 ⁇ 10 6 cells / ml, and in the present invention through epitope screening Selected 3-4 peptides were added at a concentration of 1 ⁇ g / ml each. These cell suspensions were dispensed in 1 ml aliquots into 14 ml round tubes and incubated in a CO 2 incubator.
- CTL medium RPMI1640 medium + 4 mM L-glutamine + 12.5 mM HEPES + 50 ⁇ M 2-mercaptoethanol + 3% autoplasma
- the washed cells were suspended in CTL medium at a concentration of 2 ⁇ 10 6 cells / ml, and then cultured by adding each of the same 3-4 peptides at a concentration of 5 ⁇ g / ml.
- PBMCs were collected and washed twice with RPMI1640 medium, then suspended in CTL medium at a concentration of 5 ⁇ 10 6 cells / ml and 50 U / ml IL-2 was added. .
- PBMCs Isolate PBMCs from normal donors, suspend them at 1 ⁇ 10 8 cells / ml, irradiate at 3000 rad to induce cell death, and provide costimulation for inducing proliferation of T cells. Can be used as a culture additive.
- FIG. 14 shows three types of hTERT peptides [CLKELVARV (SEQ ID NO: 1), PLFLELL (SEQ ID NO: 2), AAVTPAA (SEQ ID NO: 3)] by separating PBMC from 50 cc blood of gastric cancer patients with HLA-A * 24 allele. Each was added at a concentration of 1 ⁇ g / ml, followed by culture according to the procedure described in “(1) Proliferation of (1) Autologous Cancer Antigen-Specific CD8 T Cells” of Example 3. On the 14th day of culture, all cells were harvested and T cells proliferated in response to hTERT peptide were isolated / proliferated according to “(2) Screening of autologous cancer antigen specific CD8 T cells”.
- the isolated T cells were cultured at a level that can be administered to cancer patients through the “(3) mass culture of autocancerous antigen specific CD8 T cells” process, and the final cultured cells had a specific TCRVb type with low aging and function. Flow cytometry was determined to be T cells.
- 15 is a diagram illustrating a pilot production process of a WT1 T cell therapeutic agent.
- FIG. 15 shows four types of WT1 peptide [SLGEQQVSV (SEQ ID NO: 4), RMFPNAPVL (SEQ ID NO: 5), CMTWNQMNL (SEQ ID NO: 6) by separating PBMC from 50 cc blood of malignant glioma patients with HLA-A * 02 allele. , VLDFAPPGA (SEQ ID NO: 7)] was added at a concentration of 1 ⁇ g / ml, and then cultured according to the procedure described in “(1) Proliferation of (1) Autologous Antigen Specific CD8 T Cells”.
- T cells proliferated in response to WT1 peptide were isolated / proliferated according to “(2) Screening of autologous antigen-specific CD8 T cells”.
- the isolated T cells were cultured at a level that can be administered to cancer patients through the “(3) mass culture of autocancerous antigen specific CD8 T cells” process, and the final cultured cells had a specific TCRVb type with low aging and function. Flow cytometry was determined to be T cells.
- FIG. 16 is a diagram illustrating a pilot production process of NY-ES01 T cell therapeutic agent.
- FIG. 16 shows four types of NY-ESO1 peptide [SISSCLQQL (SEQ ID NO: 8), RLLEFYLAM (SEQ ID NO: 9), GVLLKEFTV (SEQ ID NO: 10), isolated from 50 cc blood of ovarian cancer patients with HLA-A * 02 allele. ), ILTIRLTAA (SEQ ID NO: 11)] were each added at a concentration of 1 ⁇ g / ml, and then cultured according to the procedure described in “(1) Proliferation of (1) Autologous Antigen Specific CD8 T Cells”.
- T cells proliferated in response to NY-ESO-1 peptide were isolated / proliferated according to “(2) Selection of autologous cancer antigen specific CD8 T cells”.
- the isolated T cells were cultured at a level that can be administered to cancer patients through the “(3) mass culture of autocancerous antigen specific CD8 T cells” process, and the final cultured cells had a specific TCRVb type with low aging and function. Flow cytometry was determined to be T cells.
- 17 is a diagram illustrating a pilot production process of a MAGE-A3 T cell therapeutic agent.
- FIG. 17 shows four types of MAGE-A3 peptide [LLIIVLAII (SEQ ID NO: 12), KIWEELSVL (SEQ ID NO: 13), LVFGIELMEV (SEQ ID NO: 14), isolated from PBMC from 50cc blood of a sarcoma patient with HLA-A * 02 allele.
- SLPTTMNYPL SEQ ID NO: 15
- T cells proliferated in response to MAGE-A3 peptide were isolated / proliferated according to “(2) Screening of autologous cancer antigen specific CD8 T cells”.
- the isolated T cells were cultured at a level that can be administered to cancer patients through the “(3) mass culture of autocancerous antigen specific CD8 T cells” process, and the final cultured cells had a specific TCRVb type with low aging and function. Flow cytometry was determined to be T cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (11)
- 하기 단계들을 포함하는 자가암항원 특이적 CD8+ T 세포의 분리방법:a) 암 환자 혈액내에 존재하는 자가암항원 CD8+ T 세포 에피토프를 선별하는 단계;b) 암 환자의 혈액으로부터 분리된 PBMC(peripheral blood mononuclear cell)를 상기 에피토프의 펩티드 및 IL-2와 함께 배지에서 배양하는 단계;c) 상기 배양된 세포를 b) 단계와 동일한 펩티드를 첨가하여 4-1BB 발현을 유도하는 단계; 및d) 4-1BB 발현이 유도된 세포를 항-4-1BB 항체가 코팅된 배양 플레이트에서 배양한 후 부착하지 않은 세포를 제거하는 단계.
- 제 1항에 있어서, 상기 a) 단계의 자가암항원은 hTERT (GenBank: BAC11010.1), WT1 (GenBank: AAO61088.1), NY-ESO1 (GenBank: CAA05908.1), 및 MAGE-A3 (NCBI Reference Sequence: NP_005353.1)로 구성된 군에서 선택된 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 b) 단계에서 에피토프는 서열번호 1 내지 15로 구성된 군에서 선택된 아미노산 서열로 이루어진 펩티드인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 b) 단계의 배지는 자가혈장이 포함된 배지인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 b) 단계의 배양은 12 내지 16일 동안 수행되는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 c) 단계의 발현 유도는 12 내지 36시간 동안 배양하는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 d) 단계의 배양은 1 내지 20분간 수행되는 것을 특징으로 하는 방법.
- 제 1항에 따른 방법으로 분리된 자가암항원 특이적 CD8+ T 세포와 방사선 조사된 동종이계(allogeneic) PBMC를 IL-2, 항-CD3 항체 및 자가혈장이 포함된 배지로 현탁한 후 배양용 백에 주입하고, 상기 배지를 추가로 주입하여 배양하는 것을 포함하는 자가암항원 특이적 CD8+ T 세포의 대량배양방법.
- 제 8항에 있어서, 상기 PBMC는 정상 공여자로부터 분리된 것을 특징으로 하는 방법.
- 제 8항에 있어서, 상기 배양은 4 내지 15일간 수행되는 것을 특징으로 하는 방법.
- 제 10항에 있어서, 상기 배양은 배양 4일, 7일, 9일, 11일 및 14일째에 배지를 추가 주입하는 것을 특징으로 하는 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15761276.3A EP3118322A4 (en) | 2014-03-12 | 2015-03-11 | Method for isolating and proliferating self-tumor antigen-specific cd8+ t cells |
AU2015230611A AU2015230611B2 (en) | 2014-03-12 | 2015-03-11 | Method for isolating and proliferating self-tumor antigen-specific CD8+ T cells |
JP2016575276A JP6522671B2 (ja) | 2014-03-12 | 2015-03-11 | 自己癌抗原特異的cd8+t細胞の分離及び増殖方法 |
CN201580001522.6A CN105473731B (zh) | 2014-03-12 | 2015-03-11 | 自身癌抗原特异性cd8+ t细胞的分离及增殖方法 |
CA2942557A CA2942557C (en) | 2014-03-12 | 2015-03-11 | Methods for isolating and proliferating autologous cancer antigen-specific cd8+ t cells |
HK16109673.7A HK1224340A1 (zh) | 2014-03-12 | 2016-08-12 | 自身癌抗原特異性 細胞的分離及增殖方法 |
AU2018204924A AU2018204924B2 (en) | 2014-03-12 | 2018-07-06 | Method for isolating and proliferating self-tumor antigen-specific cd8+ t cells |
AU2020202832A AU2020202832B2 (en) | 2014-03-12 | 2020-04-29 | Method for isolating and proliferating self-tumor antigen specific cd8+ t cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140029198A KR101503341B1 (ko) | 2014-03-12 | 2014-03-12 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
KR10-2014-0029198 | 2014-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015137724A1 true WO2015137724A1 (ko) | 2015-09-17 |
Family
ID=53027809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/002356 WO2015137724A1 (ko) | 2014-03-12 | 2015-03-11 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20150259646A1 (ko) |
EP (1) | EP3118322A4 (ko) |
JP (3) | JP6522671B2 (ko) |
KR (1) | KR101503341B1 (ko) |
CN (2) | CN105473731B (ko) |
AU (3) | AU2015230611B2 (ko) |
CA (1) | CA2942557C (ko) |
HK (1) | HK1224340A1 (ko) |
WO (1) | WO2015137724A1 (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
JP2018042481A (ja) * | 2016-09-13 | 2018-03-22 | テラ株式会社 | 抗原特異的t細胞含有組成物及びその製造方法 |
CN106589133A (zh) * | 2016-10-21 | 2017-04-26 | 闾军 | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 |
MX2019004692A (es) | 2017-01-06 | 2019-11-08 | Eutilex Co Ltd | Anticuerpos 4-1bb anti-humano y usos de los mismos. |
IL273030B2 (en) * | 2017-09-05 | 2024-03-01 | Gritstone Bio Inc | Neoantigen identification for T-CELL therapy |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
KR20190120987A (ko) | 2018-04-17 | 2019-10-25 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
WO2020032780A1 (ko) | 2018-08-10 | 2020-02-13 | 주식회사 유틸렉스 | 암항원 특이적 세포독성 t세포 |
JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的cd8+t細胞を調製および凍結保存するための方法 |
CN113906141A (zh) * | 2019-03-04 | 2022-01-07 | 大学健康网络 | T细胞受体及其使用方法 |
KR102352715B1 (ko) * | 2019-04-12 | 2022-01-19 | 국립암센터 | Il-21을 이용한 항원 특이적 cd8+ t 세포의 증식 촉진 또는 대량 배양 방법 |
WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
KR20210098637A (ko) | 2020-02-03 | 2021-08-11 | 삼다바이오텍 주식회사 | Cd71을 이용한 자가암항원 반응성 cd8 t 세포 분리방법 및 이의 응용 |
CN117487000A (zh) * | 2022-08-30 | 2024-02-02 | 暨南大学 | 一种肿瘤T细胞抗原表位肽、pMHC及其制备和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224402A1 (en) * | 2003-05-08 | 2004-11-11 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific T cells |
US6905685B2 (en) * | 1988-11-07 | 2005-06-14 | Byoung S. Kwon | Methods of using antibodies to human receptor protein 4-1BB |
KR100882445B1 (ko) * | 2007-03-16 | 2009-02-09 | 울산대학교 산학협력단 | 항―4-1bb 항체를 이용한 항원 특이적 자가유래cd8+t 세포의 분리 및 증식 방법 |
KR20100043130A (ko) * | 2008-10-18 | 2010-04-28 | 울산대학교 산학협력단 | 세포 활성 조성물 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
DK1230268T3 (da) * | 1999-11-18 | 2010-02-08 | Epimmune Inc | Heteroklitiske analoger af klasse I-epitoper |
CA2392764A1 (en) | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
US20030191063A1 (en) | 2000-08-21 | 2003-10-09 | Wraith David Cameron | Peptide selection method |
KR100468321B1 (ko) | 2001-02-08 | 2005-01-27 | 학교법인 울산공업학원 | 종양 및 에이즈치료용 폴리펩타이드 |
EP2149381A3 (en) | 2001-03-09 | 2010-05-05 | Baylor Research Institute | Method of treating malignancies through induction of blood immune responses |
ES2328025T3 (es) * | 2001-10-09 | 2009-11-06 | Mayo Foundation For Medical Education And Research | Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb. |
WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
KR100500283B1 (ko) | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
AR046094A1 (es) | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Hbbk4항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
DK2016414T3 (en) | 2006-05-05 | 2015-12-07 | Opexa Therapeutics | T-cell vaccine |
KR101103603B1 (ko) * | 2008-07-25 | 2012-01-09 | 국립암센터 | 4-1bbl 펜타머 단백질을 이용한 항원 특이적 cd8+t 세포의 분리 및 증식 방법 |
SI2172211T1 (sl) | 2008-10-01 | 2015-03-31 | Immatics Biotechnologies Gmbh | Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka |
KR100882455B1 (ko) * | 2008-10-15 | 2009-02-06 | 방봉문 | 황토 기저 위에 무늬목을 마감재로 부착하는 바닥재 시공 방법 |
RU2710717C2 (ru) | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1ВВ |
ES2783026T3 (es) | 2014-02-04 | 2020-09-16 | Pfizer | Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer |
KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
JP2017517506A (ja) | 2014-05-21 | 2017-06-29 | ファイザー・インコーポレイテッド | 癌を処置するための抗ccr4抗体および4−1bbアゴニストの併用 |
US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
DE102015000928B3 (de) | 2015-01-28 | 2016-07-21 | Thyssenkrupp Ag | Vorrichtung zur Einbringung eines Hilfsdrehmoments in eine Lenkwelle einer elektromechanischen Hilfskraftlenkung |
CN107921104A (zh) | 2015-02-22 | 2018-04-17 | 索伦托治疗有限公司 | 结合cd137的抗体疗法 |
CA2989586A1 (en) | 2015-06-16 | 2016-12-22 | Pfizer, Inc. | Pd-l1 antagonist combination treatments |
US10875921B2 (en) | 2016-05-27 | 2020-12-29 | Abbvie Biotherapeutics Inc. | Anti-4-1BB antibodies and their uses |
MX2019004692A (es) | 2017-01-06 | 2019-11-08 | Eutilex Co Ltd | Anticuerpos 4-1bb anti-humano y usos de los mismos. |
-
2014
- 2014-03-12 KR KR20140029198A patent/KR101503341B1/ko active IP Right Grant
-
2015
- 2015-03-11 CA CA2942557A patent/CA2942557C/en active Active
- 2015-03-11 CN CN201580001522.6A patent/CN105473731B/zh active Active
- 2015-03-11 WO PCT/KR2015/002356 patent/WO2015137724A1/ko active Application Filing
- 2015-03-11 EP EP15761276.3A patent/EP3118322A4/en active Pending
- 2015-03-11 JP JP2016575276A patent/JP6522671B2/ja active Active
- 2015-03-11 AU AU2015230611A patent/AU2015230611B2/en active Active
- 2015-03-11 CN CN201810653908.0A patent/CN108865994A/zh active Pending
- 2015-03-12 US US14/656,355 patent/US20150259646A1/en not_active Abandoned
-
2016
- 2016-08-12 HK HK16109673.7A patent/HK1224340A1/zh unknown
-
2017
- 2017-08-30 US US15/691,179 patent/US10801011B2/en active Active
-
2018
- 2018-03-26 US US15/936,209 patent/US10570371B2/en active Active
- 2018-07-06 AU AU2018204924A patent/AU2018204924B2/en active Active
- 2018-11-30 JP JP2018225159A patent/JP2019050826A/ja active Pending
-
2020
- 2020-04-28 JP JP2020079674A patent/JP7122336B2/ja active Active
- 2020-04-29 AU AU2020202832A patent/AU2020202832B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905685B2 (en) * | 1988-11-07 | 2005-06-14 | Byoung S. Kwon | Methods of using antibodies to human receptor protein 4-1BB |
US20040224402A1 (en) * | 2003-05-08 | 2004-11-11 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific T cells |
KR100882445B1 (ko) * | 2007-03-16 | 2009-02-09 | 울산대학교 산학협력단 | 항―4-1bb 항체를 이용한 항원 특이적 자가유래cd8+t 세포의 분리 및 증식 방법 |
KR20100043130A (ko) * | 2008-10-18 | 2010-04-28 | 울산대학교 산학협력단 | 세포 활성 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3118322A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2015230611A1 (en) | 2016-09-29 |
JP2017508480A (ja) | 2017-03-30 |
US20180057793A1 (en) | 2018-03-01 |
HK1224340A1 (zh) | 2017-08-18 |
AU2020202832A1 (en) | 2020-05-21 |
JP2019050826A (ja) | 2019-04-04 |
US10801011B2 (en) | 2020-10-13 |
CN108865994A (zh) | 2018-11-23 |
AU2018204924A1 (en) | 2018-07-26 |
US20150259646A1 (en) | 2015-09-17 |
US20180216066A1 (en) | 2018-08-02 |
CN105473731A (zh) | 2016-04-06 |
CN105473731B (zh) | 2018-07-20 |
CA2942557A1 (en) | 2015-09-17 |
JP6522671B2 (ja) | 2019-05-29 |
KR101503341B1 (ko) | 2015-03-18 |
CA2942557C (en) | 2023-04-04 |
AU2015230611B2 (en) | 2018-04-19 |
AU2020202832B2 (en) | 2023-02-02 |
US10570371B2 (en) | 2020-02-25 |
AU2018204924B2 (en) | 2020-01-30 |
EP3118322A4 (en) | 2017-08-16 |
EP3118322A1 (en) | 2017-01-18 |
JP2020124214A (ja) | 2020-08-20 |
JP7122336B2 (ja) | 2022-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015137724A1 (ko) | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 | |
EP0726941B1 (en) | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl | |
WO2018101782A1 (ko) | T 세포 자극용 엑소좀 및 이의 약제학적 용도 | |
WO2016085248A1 (en) | Method for culturing natural killer cells using t cells | |
WO2016209021A1 (ko) | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 | |
WO2019182422A1 (ko) | 신규 유전자 변형 자연살해 세포주 및 그의 용도 | |
Ohkusu‐Tsukada et al. | Targeted inhibition of IL‐10‐secreting CD25− Treg via p38 MAPK suppression in cancer immunotherapy | |
Salgaller et al. | Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide | |
Amir et al. | Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease | |
WO2016018053A1 (ko) | 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도 | |
US20110086367A1 (en) | Pharmaceuticals for influencing the reaction of the human immune system | |
WO2019103436A9 (ko) | Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 | |
WO2017069512A1 (ko) | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 | |
WO2017003153A1 (ko) | 제대혈 단핵세포 또는 이로부터 유래된 세포로부터 자연살해세포를 제조하는 방법 | |
WO2020032780A1 (ko) | 암항원 특이적 세포독성 t세포 | |
Chikamatsu et al. | CD4+ T helper responses in squamous cell carcinoma of the head and neck | |
Krishnadas et al. | Wilms’ tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood | |
WO2023090774A1 (ko) | 종양 침윤 림프구의 개선된 제조방법 | |
WO2023106894A1 (ko) | Mr1 제한적 panck t 세포 및 이의 제조방법 | |
WO2021157993A1 (ko) | Cd71을 이용한 자가암항원 반응성 cd8 t 세포 분리방법 및 이의 응용 | |
WO2021006420A1 (ko) | 포스포리파아제 a2를 처리하여 t 세포의 세포사멸을 조절하는 방법 | |
Munk et al. | Low-Molecular-Weight Protein Ligands from Onchocerca volvulus Preferentially Stimulate the Human γδ T Cell Vδ+ Subset | |
WESSELINOVA | T cells-do they know who they are? | |
KR20030085659A (ko) | 암 치료용 엑소좀 및 그를 이용한 암 백신 | |
강병현 | PLZF+ innate T cells support TGF-b-dependent generation of activated/memory-like regulatory T cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201580001522.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15761276 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016575276 Country of ref document: JP Kind code of ref document: A Ref document number: 2942557 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015761276 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015761276 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015230611 Country of ref document: AU Date of ref document: 20150311 Kind code of ref document: A |